List of Excipients in Branded Drug ARSENIC TRIOXIDE

Generic Drugs Containing ARSENIC TRIOXIDE

Company	Ingredient	NDC	Excipient
Sandoz Inc	arsenic trioxide	0781-3498	HYDROCHLORIC ACID
Sandoz Inc	arsenic trioxide	0781-3498	SODIUM HYDROXIDE
Sandoz Inc	arsenic trioxide	0781-3498	WATER
Nexus Pharmaceuticals LLC	arsenic trioxide	14789-600	HYDROCHLORIC ACID
Nexus Pharmaceuticals LLC	arsenic trioxide	14789-600	SODIUM HYDROXIDE
Nexus Pharmaceuticals LLC	arsenic trioxide	14789-600	WATER
Heritage Pharma Labs Inc d/b/a Avet Pharmaceuticals Inc	arsenic trioxide	23155-869	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in ARSENIC TRIOXIDE?

# Of NDCs	Excipient
23	HYDROCHLORIC ACID
23	SODIUM HYDROXIDE
20	WATER

Arsenic Trioxide Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Arsenic trioxide is a technically simple but commercially constrained injectable. The core formulation challenge is maintaining arsenic trioxide in solution at a controlled alkaline pH while limiting precipitation, adsorption, leachables, dosing errors, and occupational exposure. The strongest opportunities are ready-to-administer presentations, pediatric dose flexibility, infusion compatibility, container-closure systems, and manufacturing platforms that reduce waste and handling risk.

The U.S. reference product, Trisenox, is a preservative-free 1 mg/mL intravenous solution. Its listed excipients are sodium hydroxide and hydrochloric acid for pH adjustment, with water for injection as the vehicle. The product is diluted before administration in 5% dextrose injection or 0.9% sodium chloride injection. [1]

What excipients are used in arsenic trioxide injection?

The marketed reference formulation uses a minimal excipient system.

Component	Function	Commercial significance
Arsenic trioxide	Active pharmaceutical ingredient	Requires controlled concentration, oxidation state, and impurity profile
Water for injection	Vehicle	Supports parenteral administration and dilution
Sodium hydroxide	pH adjustment and solubilization support	Helps maintain the alkaline solution environment
Hydrochloric acid	Final pH adjustment	Controls product pH after alkaline dissolution
No preservative	Avoids preservative toxicity and compatibility issues	Supports oncology and pediatric use

The labeled pH range for Trisenox is approximately 7.5 to 8.5. The formulation is administered intravenously after dilution and is not intended for direct undiluted injection. [1]

Arsenic trioxide has limited solubility in neutral aqueous systems and is more readily maintained in solution under alkaline conditions. The formulation therefore depends more on pH control and process precision than on a complex excipient platform.

Why is the excipient list so short?

A short excipient system reduces several risks:

• Additional excipients may complex arsenic or change its bioavailability.
• Organic buffers can introduce degradation or compatibility pathways.
• Chelating agents may change arsenic speciation and tissue distribution.
• Preservatives are unattractive for repeated oncology dosing and pediatric administration.
• Surfactants can increase extractables, adsorption, and infusion-line compatibility risks.
• Higher ionic strength can affect stability and container interaction.

The commercial consequence is that differentiation is unlikely to come from adding conventional excipients alone. The stronger strategy is to improve the delivery system while preserving a simple formulation.

What formulation properties control arsenic trioxide product performance?

Four formulation attributes dominate development risk: pH, concentration, container interaction, and infusion compatibility.

pH and arsenic speciation

The pH window must be narrow enough to maintain solubility and chemical stability without creating excessive alkalinity at the injection site after dilution. Development programs should assess:

• Arsenic trioxide concentration over shelf life
• pH drift during storage
• Visible and subvisible particulates
• Arsenic-related degradation products
• Oxidation-state changes
• Precipitation after dilution
• Compatibility with common infusion fluids

pH adjustment with sodium hydroxide and hydrochloric acid is established, inexpensive, and regulator-friendly. A novel buffer system would need a clear benefit, such as improved stability, lower precipitation risk, or reduced container interaction.

Concentration and dose flexibility

The reference strength is 1 mg/mL. Dose calculations depend on patient body weight, treatment phase, and combination therapy. A formulation that supports accurate withdrawal of small volumes has value in pediatric and low-body-weight patients.

Commercial options include:

• A lower-strength presentation for pediatric dosing
• A higher-strength concentrate that reduces infusion volume
• A unit-dose vial or prefilled infusion container
• A ready-to-administer bag with labeled total arsenic trioxide content
• A pharmacy compounding kit with validated transfer components

A higher concentration is commercially attractive only if solubility, pH, viscosity, infusion tolerability, and dosing accuracy remain acceptable.

Container-closure compatibility

Arsenic-containing solutions require extractables and leachables testing for:

• Glass vials
• Elastomeric stoppers
• Plastic infusion bags
• Transfer devices
• Syringes
• Tubing
• Filters
• Administration sets

Potential risks include adsorption to polymer surfaces, migration of organic compounds into solution, pH-mediated container degradation, and arsenic loss during storage. The container system can be a meaningful product differentiator even when the liquid formulation is conventional.

What ready-to-use opportunities exist for arsenic trioxide?

The strongest near-term opportunity is a ready-to-administer formulation that eliminates pharmacy dilution.

Ready-to-administer infusion bags

A premixed infusion bag could reduce:

• Pharmacy preparation time
• Manipulation of a cytotoxic or hazardous drug
• Dose calculation errors
• Waste from partially used vials
• Exposure during transfer and dilution
• Variability in final infusion concentration

The product would need validated stability in the selected bag, tubing, and administration system. The label would also need clear instructions on storage, in-use stability, particulate inspection, and administration duration.

A commercial product could use a pharmacy-ready concentration rather than a single fixed patient dose. For example, a standardized infusion concentration may fit hospital protocols while reducing compounding steps.

Closed-system transfer and compounding accessories

A lower-complexity opportunity is a kit combining the existing vial with:

• A closed-system transfer device
• A compatible syringe or transfer set
• A validated filter
• A labeled diluent
• A dose-calculation worksheet or electronic dosing support

This approach may require less formulation development than a new liquid presentation. The commercial value would come from workflow, safety, and hospital purchasing integration.

Pediatric presentations

Pediatric acute promyelocytic leukemia requires weight-based dosing. A product designed for small doses could reduce the amount discarded from a standard vial. Opportunities include:

• Smaller fill-volume vials
• Lower concentration presentations
• Unit-dose syringes
• Ready-to-use pediatric infusion containers
• Pack sizes calibrated to common body-weight bands

Any pediatric formulation must address preservative avoidance, dosing accuracy, tamper resistance, and compatibility with pediatric infusion systems.

How can excipients create differentiation without changing arsenic exposure?

The safest development strategy is to treat excipients as enabling components rather than pharmacologically active differentiators.

Buffer optimization

A carefully selected buffer may improve pH control during storage and dilution. The candidate must not:

• Bind arsenic strongly
• Alter arsenic species
• Increase toxicity
• Cause precipitation with saline or dextrose
• Increase osmolality beyond acceptable limits
• Create new impurity pathways

Phosphate and citrate systems would require particular scrutiny because they can alter ionic interactions and metal-related chemistry. A simple hydroxide/acid pH-adjustment system remains easier to justify unless a buffer provides measurable stability or handling benefits.

Tonicity adjustment

The reference product is diluted before infusion, reducing the need for a tonicity agent in the concentrate. Adding sodium chloride or another tonicity modifier may increase ionic strength and affect stability. Tonicity adjustment is more relevant for a ready-to-inject or low-volume presentation than for the existing concentrate.

Surfactants and solubilizers

Surfactants are unlikely to be the first-choice strategy because arsenic trioxide does not require a conventional emulsion or micellar system. Surfactants may increase:

• Leachables
• Foaming
• Adsorption variability
• Infusion compatibility concerns
• Regulatory characterization requirements

Their use would be justified only if they solve a defined problem such as concentration increase, container adsorption, or precipitation after dilution.

Antioxidants and chelators

Antioxidants and chelators require a high evidentiary threshold. They may change arsenic chemistry, alter pharmacokinetics, or interfere with the active species. Such excipients could create more regulatory risk than commercial value unless supported by detailed mechanistic and toxicological data.

What manufacturing and intellectual-property barriers affect arsenic trioxide products?

The active ingredient is an established small molecule, and the basic aqueous formulation is not inherently difficult to reproduce. The main barriers are process control, impurity management, sterility assurance, and compatibility data.

Manufacturing barriers

Critical manufacturing controls include:

• Arsenic trioxide identity and purity
• Control of arsenic-related impurities
• pH adjustment sequence
• Mixing uniformity
• Sterile filtration or aseptic processing
• Particulate control
• Container-closure integrity
• Cleaning validation for arsenic residues
• Worker exposure controls
• Disposal of arsenic-containing waste

Arsenic handling creates a facility and occupational-safety burden that is higher than for many conventional oncology injectables. Dedicated equipment, validated cleaning, and waste controls can raise the cost of entry.

Formulation and device patents

The strongest patentable subject matter is more likely to involve:

• A specific stable concentration range
• A defined pH and impurity profile
• A ready-to-administer container
• A low-adsorption packaging system
• A closed-transfer device
• A stable premixed infusion bag
• A pediatric dosing presentation
• A manufacturing process that reduces arsenic residues
• A specific combination of formulation and administration method

A simple formulation containing arsenic trioxide, water, sodium hydroxide, and hydrochloric acid is likely to face a higher obviousness risk than a product with demonstrated stability or handling advantages. Commercial exclusivity may therefore depend on device, packaging, process, or workflow claims rather than composition claims alone.

What is the FDA regulatory status of arsenic trioxide?

Trisenox received U.S. approval for relapsed or refractory acute promyelocytic leukemia and later gained broader use in newly diagnosed low- or intermediate-risk APL in combination with tretinoin. [1,2] Arsenic trioxide is also incorporated into major treatment guidelines for APL. [3]

The principal U.S. regulatory pathways are:

Product concept	Likely regulatory route
Generic 1 mg/mL injectable equivalent	Abbreviated New Drug Application
New concentration or formulation	505(b)(2) application
Ready-to-administer bag	505(b)(2) or NDA, depending on differences and data
New device-led presentation	Drug-device combination assessment
New clinical use	Supplemental application or new application
Pediatric dose presentation	ANDA supplement or 505(b)(2), depending on formulation changes

A formulation change that affects concentration, excipients, container, dilution, or administration may require comparative stability, compatibility, and clinical bridging. Bioequivalence expectations for an injectable solution can differ from those for oral products, but sameness of formulation and route remains important.

When does arsenic trioxide lose exclusivity, and what is the generic risk?

The original small-molecule exclusivity period has long expired. Generic arsenic trioxide injections are commercially feasible, and the reference product faces price pressure from injectable competitors.

Because arsenic trioxide is a small molecule, biosimilar risk does not apply. The relevant competitive threats are:

• Generic injectable products
• Hospital-compounded alternatives
• Ready-to-use oncology admixture services
• Contract manufacturing organizations
• Premixed infusion products
• Combination regimens that reduce use of competing APL products

Paragraph IV litigation risk depends on current Orange Book listings and any unexpired patents associated with the reference product or approved formulations. The highest litigation exposure would generally arise from a generic seeking approval for a formulation, container, method of use, or delivery system with an active patent listing. The basic active ingredient is not the principal source of long-term exclusivity.

How strong is the commercial opportunity for excipient-enabled arsenic trioxide products?

The opportunity is moderate for workflow products and narrower for new chemical formulations.

Opportunity	Development complexity	Commercial potential
Generic 1 mg/mL vial	Low to moderate	High volume, price competition
Smaller pediatric vial	Moderate	Moderate, waste reduction
Ready-to-administer infusion bag	Moderate to high	High hospital value
Closed-system transfer kit	Moderate	Moderate, safety-driven
Higher-concentration product	High	Moderate, dependent on stability
Novel buffer system	High	Low to moderate unless benefit is proven
Prefilled syringe	High	Selective, dose and stability constraints
Lyophilized product	High	Limited unless it materially improves shelf life
Combination formulation with tretinoin	High	Potentially strategic, but clinically and regulatorily complex

The most defensible commercial proposition is reduction of total treatment cost rather than a higher active-drug price. Hospitals may value lower preparation time, fewer manipulations, less drug waste, simpler inventory, and reduced hazardous-drug exposure.

How does arsenic trioxide compare with competing APL products?

Arsenic trioxide competes primarily with all-trans retinoic acid-based regimens, anthracycline-containing therapy, and other arsenic trioxide products rather than with biologics.

Attribute	Arsenic trioxide injection	Oral tretinoin	Anthracycline-based therapy
Dosage form	Intravenous	Oral	Intravenous
Excipient opportunity	High in bags, containers, and compatibility	High in oral formulations	Moderate
Main formulation issue	pH, precipitation, adsorption, infusion compatibility	Solubility and oral exposure	Stability and infusion handling
Biosimilar relevance	None	None	None
Hospital workflow burden	High without premix	Lower	High
Main differentiation route	Ready-to-use delivery and safety	Oral delivery and tolerability	Regimen selection and toxicity

Arsenic trioxide has a particular opportunity in standardized APL pathways because treatment may be protocolized and administered over repeated cycles. That pattern supports premixed and dose-optimized products.

What patent litigation and settlement issues matter?

Patent litigation is more likely to concern formulation or delivery innovations than the active ingredient itself. Relevant issues include:

• Whether a generic product uses the same excipient system
• Whether a ready-to-use product infringes packaging claims
• Whether a method-of-use patent covers newly diagnosed or relapsed APL
• Whether a settlement restricts launch timing
• Whether a product is listed in the FDA Orange Book
• Whether a patent covers the drug, container, or administration method

A commercial diligence review should separate three rights categories: active-ingredient patents, formulation patents, and device or packaging patents. They have different validity profiles, infringement theories, and launch implications.

Key Takeaways

• The reference arsenic trioxide formulation is a simple preservative-free aqueous solution using sodium hydroxide and hydrochloric acid for pH adjustment.
• The main technical risks are pH drift, precipitation, arsenic speciation, adsorption, leachables, particulate formation, and container compatibility.
• The strongest commercial opportunity is a ready-to-administer infusion product that reduces pharmacy compounding and hazardous-drug handling.
• Pediatric dose flexibility and smaller fill volumes can reduce drug waste and improve dosing accuracy.
• Novel buffers, surfactants, antioxidants, and chelators require strong mechanistic justification because they may alter arsenic chemistry.
• Generic competition is established or feasible because the original small-molecule exclusivity period has expired.
• Biosimilar risk does not apply.
• Formulation, packaging, closed-transfer, and manufacturing-process claims offer more realistic differentiation than a basic arsenic trioxide composition claim.
• The principal regulatory pathways are an ANDA for an equivalent injectable and a 505(b)(2) application for materially different formulations or delivery systems.
• Commercial value will depend on hospital workflow savings, product reliability, waste reduction, and safety controls.

FAQs About Arsenic Trioxide Excipient Development

Can arsenic trioxide be formulated without sodium hydroxide?

It may be possible, but the alternative system must maintain solubility, pH, stability, and acceptable impurity levels. Sodium hydroxide is attractive because it supports alkaline solubilization without introducing a complex organic excipient.

Is a ready-to-use arsenic trioxide infusion eligible for 505(b)(2) approval?

A ready-to-use product with meaningful differences in concentration, container, dilution requirements, or administration may be suitable for a 505(b)(2) strategy. The precise pathway depends on the formulation and the reference-product relationship.

Are prefilled syringes commercially viable for arsenic trioxide?

They are technically possible but face dose variability, container compatibility, extractables and leachables, stability, and hazardous-drug handling requirements. Prefilled syringes are more suitable for standardized doses than for broad weight-based dosing.

Can excipients reduce arsenic trioxide toxicity?

Excipients should not be positioned as toxicity-reducing agents without clinical evidence. Their more credible role is to improve dose accuracy, reduce preparation errors, and limit occupational exposure.

What is the most valuable patent position for a new arsenic trioxide product?

A validated ready-to-administer system with defined stability, low adsorption, compatible packaging, and reduced preparation steps is generally more commercially defensible than a routine aqueous composition with conventional pH adjustment.

References

1. U.S. Food and Drug Administration. (2023). Trisenox (arsenic trioxide) injection prescribing information.
2. U.S. Food and Drug Administration. (2018). FDA approves arsenic trioxide combination for newly diagnosed acute promyelocytic leukemia.
3. National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Acute myeloid leukemia.
4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.
5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.
6. International Council for Harmonisation. (2006). ICH Q3D(R2): Guideline for elemental impurities.